New gut illness in Big Country: Fever, nausea, and diarrhea symptoms
ABILENE, Texas () – A new sickness is spreading through the Big Country, with symptoms including fever, nausea, and diarrhea.
Many in the Big Country opt to stay home after the latest sickness sweeps through our area. The sickness is gut-biased, with patients suffering from symptoms like fever, abdominal pain, nausea, and diarrhea. My Emergency Room 24/7, located at 4438 S Clack Street, says its phones have been ringing nonstop from people seeking relief from these symptoms. Emergency Medicine Physician for My Emergency Room 24/7, Dr. Rena Salyer, spoke to potential origins for this current ailment.
'You can name a million things. It could be a bacterium that is working its way through our water supply; it could be any number of viruses that are in our environment and that we pass from one another,' Dr. Salyer said.
While these symptoms are unpleasant, Dr. Salyer describes how they are short-lived but could develop into complications for more serious issues.
'For most folks, it seems to be self-limited just a couple of days. Folks that are having some problems… I've got a few patients where it's just obliterated their gut biome, and they get a secondary infection called the C Diff, which is very problematic and difficult to treat,' Dr. Salyer said.
Dr. Salyer went on to elaborate on how the severity of these symptoms for some people largely stems from what we choose to eat and that consuming fewer processed foods can lead to better overall gut health.
'I think that it's only problematic because we have less of the good bacteria in our colon, and then we're used to the probiotics that we take now, with the important ones being bifidobacteria and lactobacillus. We're just not getting those in our food anymore,' Dr. Salyer said.
The experts at My Emergency Room 24/7 say the best ways to counteract the sickness are to reduce proximity to those who are already sick and take proper safety precautions, such as wiping down infected surfaces and thoroughly washing your hands.
BigCountryHomepage contacted the Abilene Taylor County Public Health District for more insight into this rise. Officials stated that water samples tested over the past couple of weeks have returned pathogens in the local supply.
The health district has confirmed that the illness is Norovirus, a highly contagious virus that spreads through contaminated food and water and physical contact. Fortunately, the symptoms usually last just a couple of days, and most people recover quickly.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
MAP: Boil water advisory issued for some WaterPro customers in Draper
DRAPER, Utah () — The Salt Lake County Health Department issued a boil water advisory for some WaterPro customers in Draper on Thursday around 6 p.m. WaterPro notified affected customers that there has been potential contamination to the drinking water system, outlined in the below. As a precaution, the Utah Division of Drinking Water issued a . WaterPro-Water-System-Potentially-Affected-AreaDownload WaterPro is one of two water utilities that serves Draper City, and customers served by the Draper City water company are not affected. According to WaterPro, the contamination came from a cross-connection between secondary and culinary water systems, allowing untreated water to enter the drinking water system. WaterPro is reportedly testing to determine bacteria levels in the water supply, and so far, chlorine levels observed have been normal. Residents and businesses in the affected area should boil tap water before using it or use bottled water. In order to properly boil water, it needs to be brought to a rolling boil for at least one minute and cooled before using it. Salt Lake County Health Department said that boiled or bottled water should be used for the following things until further notice: Drinking (pets and people) Making ice Brushing teeth Washing dishes Washing produce Bathing/showering Baby formula Food preparation Humidifiers, CPAP, and other medical devices Discard any stored water, drinks, and ice made from the water supply in the last 24 hours. Flush any humidifiers, CPAP, and other medical devices with boiled or bottled water. After the order is lifted, flush all water dispensers (including on refrigerators) and discard all ice made for 24 hours. According to the Salt Lake County Health Department, contaminated water can possibly expose you to: Bacteria (e.g., E. coli, Salmonella) Viruses (e.g., Norovirus, Hepatitis A) Parasites (e.g., Cryptosporidium) Chemical contaminants (e.g., fertilizers, pesticides) Drinking untreated water, or using it to bathe or brush teeth, can cause: Nausea, vomiting, stomach cramps or diarrhea Headache, fever or flu-like symptoms More severe illness in young children, older adults or those with weakened immune systems The Health Department urges anyone in the affected area who develops these symptoms to contact their health care provider. The full boil order is included below. WaterPro-Public-Notice-Potential-Water-ContaminationDownload Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Wire
3 days ago
- Business Wire
ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, announces discovery of a highly conserved epitope across all four dengue virus serotypes using its proprietary LENS ai ™ platform powered by their patented HYFT® technology. This discovery, made using several proprietary HYFT-based analyses, identifies a part of the virus (an epitope) that has remained unmutated across all four known virus serotypes, therefore potentially allowing an epitope-based vaccine to target and activate the immune system to eliminate the virus. This discovery marks a major milestone toward the development of a potential universal dengue vaccine and validates the Company's newly launched, HYFT pattern-patented AI-native vaccine discovery engine. Unlike traditional trial-and-error methods, IPA's discovery was achieved entirely in silico, demonstrating the platform's power to translate complex biological data into actionable vaccine design. Share Dr. Jennifer Bath, ImmunoPrecise Antibodies CEO commented, 'This breakthrough highlights a new frontier in AI-driven biology—where discovery is rooted in the biology of a virus itself. By confirming that our sequence-derived patented HYFT patterns match structural signatures across all dengue serotypes, we're setting the stage for a universal vaccine design framework. Ultimately, this research validates a persistent target that may allow doctors to home in on a signal to eliminate the virus regardless of mutations that may have occurred. More importantly, the implications appear to stretch far beyond the dengue virus. This is a foundation that research indicates can now be applied to many other infectious diseases and potentially even certain types of cancer.' Building on this success in dengue, IPA now intends to extend its AI-driven vaccine design platform to other high-impact infectious diseases, for example, HIV, Norovirus, and an improved RSV vaccine. Early-stage assessments are also underway to explore the platform's application in oncology for neoantigen vaccine development and tumor-specific epitope mapping. This discovery underscores IPA's commitment to advancing drug discovery through innovative, human-relevant AI technologies that align with evolving industry standards. Using HYFT's patented ability to map biologically meaningful sub-sequence patterns across the entire biosphere, the Company's proprietary LENS ai platform identified a unique epitope shared across all four serotypes of the dengue virus—DENV-1, DENV-2, DENV-3, and DENV-4. These serotypes are distinct versions of the virus that circulate globally, and because infection with one does not protect against the others, identifying a common target is a critical step toward developing a broadly protective dengue vaccine. Unlike traditional trial-and-error methods, IPA's discovery was achieved entirely in silico, demonstrating the platform's power to translate complex biological data into actionable vaccine design. Breaking the Dengue Barrier: Patented HYFT-Powered AI Achieves What Decades of Science Could Not Why Has a Universal Dengue Vaccine Been So Elusive? Dengue is not just one virus—it's four distinct, rapidly-evolving serotypes. Immunity to one does not guarantee protection from the others, and prior infection can even make subsequent disease worse. For decades, vaccine researchers have struggled to find a viral component that is both exposed and truly conserved across all four types—a challenge compounded by the virus's rapid mutation and complex immune interactions. Traditional methods, whether experimental or computational, have repeatedly fallen short, unable to fully bridge the gap between sequence, structure, and function at a meaningful scale. Confirmed Breakthrough: Sequence and Structural HYFT Match Across All Four Serotypes IPA's discovery is a landmark moment in computational vaccinology. Using its proprietary LENSai™ platform powered by their patented HYFT® technology, the company has identified a strictly conserved epitope across all four dengue virus serotypes— a viral signature that remains unchanged despite mutations and serotype variation, and that can be targeted to trigger the immune system in efforts to eliminate the virus. This achievement marks a critical milestone in the quest for a universal dengue vaccine. What sets this apart is the depth of validation: Patented HYFT patterns, derived based on the conservation of sequence data. were independently confirmed to match corresponding structural HYFTs across all four dengue serotypes. This was made possible through LENS ai 's integration of over 20 million proprietary Structural HYFTs (S-HYFTs), enabling the platform to overlay three-dimensional conformations onto sequence-level, biology-native fingerprints. The validation demonstrates that LENS ai doesn't simply identify linear motifs—it can infer conformational and functional structures from sequence data alone, bypassing the need for time-consuming experimental techniques like crystallography or cryo-EM. This milestone affirms the patented HYFT technology's unique ability to traverse the full biological hierarchy—from DNA/RNA sequence to molecular structure to therapeutic relevance. It signals that AI-native models, rooted in biology-first principles, can now deliver actionable insights previously achievable only through years of wet-lab research. The end-to-end LENS ai platform integrates patented HYFT® universal fingerprints with deep learning, structural predictions, and literature-mined knowledge graphs to rapidly identify and refine candidate epitopes—without requiring lab-based inputs. The result: full immunogen design and in silico immunogenicity screening, dramatically reducing the time and cost of early-stage vaccine development and unlocking new opportunities to tackle even the most complex viral challenges. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the discovery and development of therapeutic antibodies and is known for solving complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the 'IPA Family'). Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as "expects," "intends," "plans," "anticipates," "believes," or similar expressions, or statements that certain actions, events, or results "may," "will," "could," or "might" occur or be achieved. These statements include, but are not limited to, those related to the anticipated benefits, scalability, adoption, and broader application of the LENS ai ™ and HYFT® platforms; the advancement and regulatory acceptance of AI-native drug discovery and vaccine development methods; the expansion of IPA's discovery engine to additional infectious disease and oncology targets; and the Company's ongoing ability to maintain scientific, regulatory, and commercial momentum. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. Such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance, competitive or market dynamics, intellectual property protection and enforcement, integration or operational risks, and changes in economic or business conditions. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.
CBS News
5 days ago
- CBS News
Will norovirus surge early again this year? CDC urges tracking of new strain.
After years of largely predictable norovirus waves, the emergence of a new strain might have disrupted the seasonal pattern of outbreaks from this notorious stomach bug, suggests a new report by the Centers for Disease Control and Prevention. In previous years, the U.S. usually saw norovirus outbreaks increase around December. That marked the start of the season for the virus. But last year's season started in October, as a new norovirus strain called GII.17 drove a record wave of outbreaks. "Continued surveillance is needed to determine if this genotype remains the dominant genotype, as well as whether the norovirus season continues to start earlier than previous years," wrote two of CDC's top norovirus researchers, in an article published this month by the agency's Emerging Infectious Diseases journal. Outbreaks have since slowed to usual levels. But with GII.17 now identified in more than 3 in 4 outbreaks in the U.S., its displacement of the GII.4 strain that had previously been dominant is raising questions about whether norovirus season could arrive early again. "GII.4 viruses are the main driver for norovirus seasonality. With the decrease of GII.4 outbreaks since 2024, whether GII.17 viruses will continue to cause an earlier onset of the norovirus season cannot yet be determined," the CDC researchers wrote. Several other countries also saw unusually large or shifted waves of norovirus this past year, after GII.17 surged to dominance. In England, norovirus reports reached levels more than double recent seasons. GII.17 was the most frequently reported genotype of norovirus through April, far above GII.4. In Japan, where GII.17 previously drove a wave of infections a decade ago, local health authorities in Tokyo reported a steep wave of infectious gastroenteritis — most from norovirus — that peaked weeks later than previous seasons and remains above recent years. Miranda de Graaf, a scientist at Erasmus University Medical Center in the Netherlands coordinating the global NoroNet network of norovirus researchers, said the Dutch nation did not see an earlier start to its norovirus season. But the country did see higher numbers of norovirus outbreaks, including a few large outbreaks in between when the usual seasonal surges occurred. GII.4 was still being detected around the world, meaning it was possible that GII.17's dominance could be short-lived, de Graaf said. Researchers had previously wondered if GII.17 could permanently take over, only to see GII.4 cases continue to remain dominant. "GII.17 only replaced GII.4 last year, and there has not been another seasonal peak after that. Therefore it is not clear if these shifts will last, or if GII.17 will be the predominant strain next winter season," de Graaf said in an email. Benjamin Lopman, an epidemiology professor at Emory University who previously worked for the CDC's viral diseases division, said shifts in norovirus strains happen "when new variants find ways around the immunity that people have built up" to previous strains. He said that new strains usually trigger more frequent outbreaks earlier in the season. "I expect we'll see outbreak patterns return to more typical levels and seasonal patterns in the coming years, though it's always challenging to predict how these viruses will behave," Lopman said in an email.
